



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Lirentelimab

Cat. No.:	HY-P99371
CAS No.:	2283348-97-8
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis<sup>[1]</sup>.</p>								
<b>In Vitro</b>	<p>Monovalent Lirentelimab fragment antigen-binding (fab) binds to recombinant SIGLEC8 extracellular domain (ECD) is determined to be 464 pM<sup>[1]</sup>.</p> <p>Lirentelimab shows high affinity to SIGLEC8 in vitro, to SIGLEC8 expressed on eosinophils, and to NK cells via its Fc region in human blood<sup>[1]</sup>.</p> <p>Lirentelimab (1 µg/mL) selectively binds to eosinophils in human peripheral blood, and eosinophils and mast cells from human lung tissue<sup>[1]</sup>.</p> <p>Lirentelimab (0.0001-100 µg/mL; 30 min) induces apoptosis of IL-5-activated eosinophils<sup>[1]</sup>.</p> <p>Lirentelimab (30 min) shows potent antibody-dependent cell-mediated cytotoxicity (ADCC) Activity on human eosinophils with an EC<sub>50</sub> value of 1.9 ng/mL to eosinophils in peripheral blood leukocytes (PBL) preparations from healthy donors<sup>[1]</sup>.</p> <p>Lirentelimab reduces eosinophil numbers in ex vivo human tissue<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Eosinophils</td> </tr> <tr> <td>Concentration:</td> <td>10 µg/mL-1 pg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>30 min</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently induced apoptosis of IL-5-activated (50 ng/mL) eosinophils.</td> </tr> </table>	Cell Line:	Eosinophils	Concentration:	10 µg/mL-1 pg/mL	Incubation Time:	30 min	Result:	Dose-dependently induced apoptosis of IL-5-activated (50 ng/mL) eosinophils.
Cell Line:	Eosinophils								
Concentration:	10 µg/mL-1 pg/mL								
Incubation Time:	30 min								
Result:	Dose-dependently induced apoptosis of IL-5-activated (50 ng/mL) eosinophils.								
<b>In Vivo</b>	<p>Lirentelimab (100 µg; i.v. once) significantly inhibits IgE-mediated mast cell activation in a mice model of systemic anaphylaxis<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Humanized mice (NSG-SGM3) engrafts with human thymus, liver, and HSC<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>100 µg</td> </tr> </table>	Animal Model:	Humanized mice (NSG-SGM3) engrafts with human thymus, liver, and HSC <sup>[1]</sup>	Dosage:	100 µg				
Animal Model:	Humanized mice (NSG-SGM3) engrafts with human thymus, liver, and HSC <sup>[1]</sup>								
Dosage:	100 µg								

---

Administration:	Intravenous injection; 100 µg, once
Result:	Completely prevented passive systemic anaphylaxis (PSA) as shown by a lack of change in rectal temperature and symptom scores in mice.

---

## REFERENCES

---

[1]. Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. *Int Arch Allergy Immunol.* 2019;180(2):91-102.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA